Status:
ENROLLING_BY_INVITATION
The Efficacy of Topical Formulation Containing Ciplukan (Physalis Angulata Linn.) on Psoriasis Vulgaris Lesions
Lead Sponsor:
Universitas Padjadjaran
Conditions:
Psoriasis Vulgaris
Inflammation
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
PHASE2
Brief Summary
Psoriasis vulgaris is a chronic inflammatory skin disease mediated by the immune system, with a complex pathogenesis that requires long-term therapy. Various inflammatory mediators that activate and a...
Detailed Description
Ciplukan (Physalis angulata Linn.) contains seco-steroids and flavonoids, which exhibit anti-inflammatory, antiproliferative, and immunosuppressive effects. These effects suggest that ciplukan (Physal...
Eligibility Criteria
Inclusion
- Age 18 - 60 years
- Diagnosed with psoriasis vulgaris based on medical history, physical examination, and severity assessment using the PASI score
Exclusion
- Pregnant or breastfeeding women.
- Patients currently undergoing systemic therapy for psoriasis vulgaris.
- Patients who have not discontinued systemic therapy/phototherapy for psoriasis vulgaris ≤ 30 days.
- Patients with psoriasis vulgaris who have not discontinued topical therapy (other than moisturizers) ≤ 14 days.
- Psoriasis vulgaris lesions located in trauma-prone areas, palms, soles, face, and skin folds.
Key Trial Info
Start Date :
February 13 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 10 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06887322
Start Date
February 13 2025
End Date
April 10 2025
Last Update
April 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hasan Sadikin General Hospital
Bandung, West Java, Indonesia, 40161